Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment.

Glioblastoma multiforme (GBM) is a highly malignant brain tumor. The blood-brain barrier (BBB) provides a major obstacle to chemotherapy since therapeutic doses cannot be achieved by traditional drug delivery without severe systemic cytotoxic effects. Recently, microbubble (MB)-enhanced focused ultrasound (FUS) was shown to temporally and locally disrupt the BBB thereby enhancing drug delivery into brain tumors. Here we propose the concept of smart, multifunctional MBs capable of facilitating FUS-induced BBB disruption while serving as drug-carrying vehicles and protecting drugs from rapid degradation. The designed MBs had a high loading capacity (efficiency of 68.01 ± 4.35%) for 1,3-bis(2-chloroethyl)-1- nitrosourea (BCNU). When combined with FUS (1-MHz), these BCNU-MBs facilitated local BBB disruption and simultaneously released BCNU at the target site, thus increasing local BCNU deposition. Encapsulation of BCNU in MBs prolonged its circulatory half-life by 5-fold, and accumulation of BCNU in the liver was reduced 5-fold due to the slow reticuloendothelial system uptake of BCNU-MBs. In tumor-bearing animals, BCNU-MBs with FUS controlled tumor progression (915.3%-39.6%) and improved median survival (29 days-32.5 days). This study provides a new approach for designing multifunctional MBs to facilitate FUS-mediated chemotherapy for brain tumor treatment.

[1]  A. Göpferich,et al.  Efficacy of BCNU and paclitaxel loaded subcutaneous implants in the interstitial chemotherapy of U-87 MG human glioblastoma xenografts. , 2002, International journal of pharmaceutics.

[2]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[3]  Robert Langer,et al.  In vivo delivery of BCNU from a MEMS device to a tumor model. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[4]  A. Huang,et al.  Possibilities of new therapeutic strategies in brain tumors. , 2010, Cancer treatment reviews.

[5]  Natalia Vykhodtseva,et al.  Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI‐guided focused ultrasound , 2007, International journal of cancer.

[6]  E P Frenkel,et al.  Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Zhigang Wang,et al.  Antitumor Effect of Docetaxel‐Loaded Lipid Microbubbles Combined With Ultrasound‐Targeted Microbubble Activation on VX2 Rabbit Liver Tumors , 2010, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[8]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[9]  C. Marosi Chemotherapy for malignant gliomas , 2006, Wiener Medizinische Wochenschrift.

[10]  Conrad Coester,et al.  New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: Part I--Formulation development and in-vitro characterization. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[11]  A. Kolozsvary,et al.  Increased tumor cures using combined radiosurgery and BCNU in the treatment of 9l glioma in the rat brain. , 2000, International journal of radiation oncology, biology, physics.

[12]  Manfred Westphal,et al.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.

[13]  Meng-Lin Li,et al.  In vivo imaging of blood flow in the mouse Achilles tendon using high-frequency ultrasound. , 2009, Ultrasonics.

[14]  Eric C. Holland,et al.  Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma , 2010, Nature Reviews Cancer.

[15]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[16]  Victor Frenkel,et al.  Delivery of systemic chemotherapeutic agent to tumors by using focused ultrasound: study in a murine model. , 2005, Radiology.

[17]  Mu-Yi Hua,et al.  Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. , 2010, Radiology.

[18]  I. Bakker-Woudenberg,et al.  Toxicity of doxorubicin entrapped within long-circulating liposomes , 1997 .

[19]  J. Sheng,et al.  Growth Inhibition against Intracranial C6 Glioma Cells by Stereotactic Delivery of BCNU by Controlled Release from poly(D,L-lactic acid) Nanoparticles , 2009, Technology in cancer research & treatment.

[20]  Xin Wang,et al.  BCNU-loaded PEG-PLLA ultrafine fibers and their in vitro antitumor activity against Glioma C6 cells. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Ferenc A. Jolesz,et al.  Local and reversible blood–brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications , 2005, NeuroImage.

[22]  Natalia Vykhodtseva,et al.  Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. , 2008, Ultrasonics.

[23]  Igor Katsyv,et al.  Experimental approaches for the treatment of malignant gliomas. , 2010, Pharmacology & therapeutics.

[24]  Mu-Yi Hua,et al.  Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment. , 2010, Neuro-oncology.

[25]  Keith L Black,et al.  Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. , 2004, Cancer control : journal of the Moffitt Cancer Center.

[26]  Henry Brem,et al.  Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[27]  T. Cloughesy,et al.  Pharmacological blood-brain barrier modification for selective drug delivery , 1995, Journal of Neuro-Oncology.

[28]  H. Engelhard,et al.  The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. , 2000, Surgical neurology.

[29]  John C. Adair,et al.  Radiation-induced Blood–brain Barrier Damage in Astrocytoma: Relation to Elevated Gelatinase B and Urokinase , 2004, Journal of Neuro-Oncology.

[30]  Niek N. Sanders,et al.  Drug loaded microbubble design for ultrasound triggered delivery , 2009 .

[31]  Yuan Cheng,et al.  Focused Ultrasound Microbubble Destruction‐Mediated Changes in Blood‐Brain Barrier Permeability Assessed by Contrast‐Enhanced Magnetic Resonance Imaging , 2009, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[32]  V. Levin,et al.  The concept of drug dose for in vitro studies with chemotherapeutic agents. , 1978, Radiation research.

[33]  S. Cho,et al.  Evaluation of in vitro and in vivo antitumor activity of BCNU-loaded PLGA wafer against 9L gliosarcoma. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.